Gene:
ELAVL1
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  Hu antigen R; embryonic lethal, abnormal vision, drosophila, homolog-like 1
Alternate Symbols:  HuR; Hua; MelG
PharmGKB Accession Id: PA27740

Details

Cytogenetic Location: chr19 : p13.2 - p13.2
GP mRNA Boundary: chr19 : 8023457 - 8070529
GP Gene Boundary: chr19 : 8020457 - 8080529
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to ELAVL1: 2

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer research. 2004. Denkert Carsten, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. The Journal of biological chemistry. 2003. Sengupta Sibani, et al. PubMed

LinkOuts

Entrez Gene:
1994
OMIM:
603466
UCSC Genome Browser:
NM_001419
RefSeq RNA:
NM_001419
RefSeq Protein:
NP_001410
RefSeq DNA:
AC_000062
AC_000151
NC_000019
NT_077812
NW_001838480
NW_927173
UniProtKB:
ELAV1_HUMAN (Q15717)
Ensembl:
ENSG00000066044
GenAtlas:
ELAVL1
GeneCard:
ELAVL1
MutDB:
ELAVL1
ALFRED:
LO027429Y
HuGE:
ELAVL1
Comparative Toxicogenomics Database:
1994
ModBase:
Q15717
HumanCyc Gene:
HS00864
HGNC:
3312

Common Searches